Collegium PharmaceuticalNASDAQ: COLL

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Investors need to pay close attention to Collegium Pharmaceutical (COLL) stock based on the movements in the options market lately.

Collegium Pharmaceutical, Inc. (NASDAQ:COLL ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Danielle Jesse - Director, Investor Relations Michael Heffernan - Interim President and Chief Executive Officer, Founder and Chairman Scott Dreyer - Chief Commercial Officer Colleen Tupper - Chief Financial Officer Conference Call Participants Les Sulewski - Truist Securities David Amsellem - Piper Sandler Serge Belanger - Needham & Company Oren Livnat - H.C. Wainright Operator Greetings, and welcome to the Collegium Pharmaceutical Third Quarter 2024 Earnings Conference Call.

While the top- and bottom-line numbers for Collegium Pharmaceutical (COLL) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.61 per share, missing the Zacks Consensus Estimate of $1.66 per share. This compares to earnings of $1.34 per share a year ago.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Collegium Pharmaceutical (COLL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Although the revenue and EPS for Collegium Pharmaceutical (COLL) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.62 per share, beating the Zacks Consensus Estimate of $1.56 per share. This compares to earnings of $1.26 per share a year ago.